We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Thales AVS France

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Novel Sonic Beam Therapy Liquefies Tumor Tissues

By MedImaging International staff writers
Posted on 01 Nov 2021
Print article
Image: The Edison histotripsy sonic beam platform (Photo courtesy of Histonics)
Image: The Edison histotripsy sonic beam platform (Photo courtesy of Histonics)
An automated external beam system uses acoustic energy to mechanically destroy tissue in the liver without incisions, ionizing radiation, or heat.

The HistoSonics (Minneapolis, MN, USA) Edison is a sophisticated histotripsy sonic beam platform designed to deliver pulsed sound energy into the body, without any incisions or needles, that destroys tissue at the sub-cellular level. Physicians first contour and plan treatment according to shape and size of their target; once the energy required to initiate cellular destruction is determined, the acoustic pulses are delivered. Treatment is monitored in real-time, while the system automatically moves through the target area.

Histotripsy uses pulsed sound waves to induce microbubbles from gases that are naturally present in tissues. These “bubble clouds” form and collapse in microseconds, creating mechanical forces that are strong enough to destroy tissue in a non-invasive and non-thermal method. As only 20%-30% of patients with liver tumors are eligible for surgical resection, due to the presence of multiple tumors, underlying poor liver function, or general health issues, histotripsy may provide a solution. Edison has received breakthrough device designation from the U.S. Food and Drug Administration (FDA).

“The Breakthrough Device Designation is a significant milestone for our company and validates our belief that our platform offers significant advantages over existing approved or cleared alternatives,” said Mike Blue, President and CEO of HistoSonics. “Early and ongoing clinical results are promising and suggest that our ability to precisely destroy targeted liver tissue, completely non-invasively, and without the challenges associated with ionizing radiation or other locoregional therapies, provides advantages to patients and physicians that don't exist today.”

Primary liver tumors were the third leading cause of tumor related death worldwide in 2020, with approximately 906,000 new cases and 830,000 deaths globally, and 5-year survival rates less than 18%. Additionally, the liver is second only to lymph nodes as the most common site of metastatic tumors, and estimated to be present in up to 70% of patients with advanced disease from another site.

Related Links:
HistoSonics


Print article
CIRS
Sun Nuclear

Channels

Imaging IT

view channel
Illustration

Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology

The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read more

Industry News

view channel
Image: GE Healthcare to be Spun Off in 2023 to Create Pure-Play Company at Center of Precision Health (Photo courtesy of GE Healthcare)

GE Healthcare to be Spun Off in 2023 to Create Pure-Play Company at Center of Precision Health

General Electric (GE; Boston, MA, USA) plans to pursue a tax-free spin-off of GE Healthcare, creating a pure-play company at the center of precision health in early 2023. The spin-off of GE Healthcare... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.